Rosetta Genomics Announces Data Published in Leukemia Research
April 20 2015 - 8:30AM
Business Wire
Study Demonstrates Ability of Rosetta’s
microRNA Platform to Distinguish between Poor and Favorable
Prognosis in Diffuse Large B-Cell Lymphoma
Rosetta Genomics Ltd. (NASDAQ:ROSG), a leading developer and
provider of microRNA-based molecular and other diagnostics,
announces that data highlighting its microRNA platform technology
was published in Leukemia Research in an article entitled,
“microRNA signature is indicative of long term prognosis in diffuse
large B cell lymphoma.” The article can be accessed online at
www.lrjournal.com.
The study compared microRNA (miR) expression between patients
with diffuse large B-cell lymphoma (DLBCL) who had a poor prognosis
with those who had a favorable prognosis. DLBCL accounts for 30-40%
of all adult non-Hodgkin's lymphomas and is heterogeneous in terms
of clinical features and prognosis.
The study group included 83 patients with DLBCL. miR signature
from tissue biopsies was compared between patients who relapsed
within nine months from commencement of treatment (defined as poor
prognosis, n=43) and those with disease-free survival of at least
five years (defined as good prognosis, n=40). RNA was analyzed
using Rosetta’s custom microarrays. Quantitative real-time
polymerase chain reaction (qRT-PCR) was used for technical
validation of microarray results. Eight miRs were found to be
differently expressed between the two prognostic groups.
In the poor prognosis group, hsa-miR-17-5p, hsa-miR-19b-3p,
hsa-miR-20a-5p and hsa-miR-106a-5p were found to be up-regulated,
while hsa-miR-150-5p, hsa-miR-342-3p, hsa-miR-181a-5p and
hsa-miR-140-3p were found to be down-regulated, compared with the
good prognosis group.
“Our data are in agreement with previous findings showing that
miR signature is predictive of prognosis for patients with DLBCL,
although with different miRs achieving statistical significance,”
noted the study’s lead author, Prof. Meir Lahav, M.D., Institute of
Hematology, Davidoff Centre, Rabin Medical Centre, Beilinson
Hospital, Petah Tikva, Israel and Sackler School of Medicine, Tel
Aviv University, Tel Aviv, Israel.
“These are exciting data as they illustrate our proprietary
platform’s ability to identify microRNA signatures in hematologic
malignancies that can differentiate poor and favorable prognostic
groups,” noted Kenneth A. Berlin, President and Chief Executive
Officer of Rosetta Genomics. “Importantly, these data complement
our broader commitment to expand our commercial offerings and
clinical pipeline in oncology diagnostics.”
About Rosetta Cancer Testing ServicesRosetta Cancer Tests
are a series of microRNA-based diagnostic testing services offered
by Rosetta Genomics. The Rosetta Cancer Origin Test™ can accurately
identify the primary tumor type in primary and metastatic cancer
including cancer of unknown or uncertain primary (CUP). The Rosetta
Lung Cancer Test™ accurately identifies the four main subtypes of
lung cancer using small amounts of tumor cells. The Rosetta Kidney
Cancer Test™ accurately classifies the four most common kidney
tumors: clear cell renal cell carcinoma (RCC), papillary RCC,
chromophobe RCC and oncocytoma. Rosetta’s assays are designed to
provide objective diagnostic data. In the U.S. alone, Rosetta
Genomics estimates that 200,000 patients a year may benefit from
the Rosetta Cancer Origin Test™, 62,000 from the Rosetta Kidney
Cancer Test™ and 222,000 patients from the Rosetta Lung Cancer
Test™. The Company’s assays are offered directly by Rosetta
Genomics in the U.S., and through distributors around the world. In
addition to its proprietary products, the Company markets the
Rosetta Genomics PGxOne™ and EGFR and KRAS tests for Admera Health.
With the recent acquisition of PersonalizeDx, the company now
offers a broader menu of molecular and other assays for lung,
bladder, prostate and breast cancer patients. For more information,
please visit www.rosettagenomics.com. Parties interested in
ordering any of these tests can contact Rosetta Genomics at (215)
382-9000 ext. 309.
About Rosetta GenomicsRosetta develops and commercializes
a full range of microRNA-based molecular diagnostics. Founded in
2000, Rosetta’s integrative research platform combining
bioinformatics and state-of-the-art laboratory processes has led to
the discovery of hundreds of biologically validated novel human
microRNAs. Building on its strong patent position and proprietary
platform technologies, Rosetta is working on the application of
these technologies in the development and commercialization of a
full range of microRNA-based diagnostic tools. PersonalizeDx’s core
FISH, IHC and PCR-based testing capabilities and partnerships in
oncology and urology provide additional content and platforms that
complement the Rosetta offerings. Rosetta’s and PersonalizeDx’s
cancer testing services are commercially available through the
Philadelphia, PA- and Lake Forest, CA-based CAP-accredited,
CLIA-certified labs, respectively.
Forward-Looking Statement DisclaimerVarious statements in
this release concerning Rosetta’s future expectations, plans and
prospects, including without limitation, statements relating to
Rosetta's proprietary platform’s ability to identify microRNA
signatures in hematologic malignancies that can differentiate poor
and favorable prognostic groups and the extent to which this data
complements the possibilities for Rosetta's expanding its
commercial offerings and/or clinical pipeline, constitute
forward-looking statements for the purposes of the safe harbor
provisions under The Private Securities Litigation Reform Act of
1995. Actual results may differ materially from those indicated by
these forward-looking statements as a result of various important
factors, including those risks more fully discussed in the "Risk
Factors" section of Rosetta’s Annual Report on Form 20-F for the
year ended December 31, 2014 as filed with the SEC. In
addition, any forward-looking statements represent Rosetta’s views
only as of the date of this release and should not be relied upon
as representing its views as of any subsequent date. Rosetta does
not assume any obligation to update any forward-looking statements
unless required by law.
Company:Rosetta GenomicsKen Berlin, 609-419-9003President
& CEOinvestors@rosettagenomics.comorInvestor:LHAAnne
Marie Fields, 212-838-3777afields@lhai.comorBruce Voss,
310-691-7100bvoss@lhai.com
Rosetta Genomics (CE) (USOTC:ROSGQ)
Historical Stock Chart
From Mar 2024 to Apr 2024
Rosetta Genomics (CE) (USOTC:ROSGQ)
Historical Stock Chart
From Apr 2023 to Apr 2024